School of Medicine of The Federal University of Rio de Janeiro
Molecular imaging has the ability to non-invasively imaging functional aspects of different organs in the body and has been used as a bridge to translate preclinical results to the clinical scenario, playing a critical role in diagnosis and therapeutics. The evolving molecular functional imaging using specific molecular targets has great potential in translational research. In the last decades in vivo bioimaging techniques has revolutionized non-invasive evaluation.
For the non-invasive image of small animals, different modalities are available, all with inherent advantages and limitations. The choice of imaging mode depends on the parameter of interest under consideration, costs and measurement time per animal. Among the main modalities for the evaluation of functional aspects, we have nuclear medicine equipment such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). In comparison to molecules of other modalities like dyes or nanoparticles, conjugation of a radioisotope does not affect the properties of a biomolecule, and it is possible to make absolute quantification of different functional processes.
The aims of this special issue are to attract researchers in the field of pre-clinical development of new radiopharmaceuticals and those who have already translated it to a phase 1 clinical trial to show their results and share their achievements and difficulties.
Potential topics include but are not limited to the following:
New SPECT and PET radiopharmaceuticals for Cancer
New SPECT and PET radiopharmaceuticals for Cardiology
New SPECT and PET radiopharmaceuticals for Neurology
Translational results of pre-clinical studies